United States Patent 10,570,103: Lysophosphatidic Acid (LPAR) Antagonist/Modulator Patent Landscape and Claim-Validity Analysis

What does US 10,570,103 actually claim?

US Patent 10,570,103 claims methods for treating or modulating lysophosphatidic acid (LPA) receptor signaling using compounds defined by a very broad Formula I chemical Markush structure and extensive substitute ranges. The core claim structure is:

Method of treatment of an LPA-dependent disease/condition by administering a therapeutically effective amount of a Formula I compound (or salt/prodrug).
Method of reducing LPA receptor (LPAR) signal transduction by contacting LPAR with the same Formula I compound (or salt/prodrug).
Dependent claims narrow disease scope (examples: liver fibrosis, NASH, nephropathy, diabetic nephropathy) and broaden co-therapy lists (large enumerations).

The patent language is dominated by Markush-style chemical genus claiming: the “active” is not limited to one structure or one salt; it covers a large family defined around a shared scaffold.

Claim set at a glance (high level)

Claim theme	Claim numbers	Claim character
Broad treatment for any “LPA-dependent disease/condition”	1, 11, 20	Markush genus method claims
Enumerated specific Formula I exemplars (subset selection)	2, 3, 4, 19, 21	Dependent narrowing to named exemplars
Specific indication exemplars	5-6, 8-10, 17-18	Dependent narrowing to disease types
LPAR signal transduction / contact	20-22	Functional mechanism claim (contact LPAR)
Co-administration expansions	7, 10, 15-16	Broad combination therapy claim dependents
Additional dependent expansions for analog lists	23-24	Dependent on co-therapy lists

(Claims provided by user text; patent number referenced in prompt.)

How broad is the Formula I genus claim?

The independent claim 1 (and parallel claim 11) defines Formula I with:

Multiple variable substituent parameters: R^A, R^B, L^1, L^2, Ring A, Ring B, Ring C, and multiple additional substituent groups (R^C, R^D, R^E, R^F, R^G, CY, X, R^H, R^J, R^L).
Large substitution allowance for each ring and substituent:
- Halogen, cyano, nitro, hydroxyl, alkoxy, fluoroalkyl, heteroalkyl, and more.
- R^J and R^L allow many groups including heterocycles and substituted alkyl/aryl/heteroaryl fragments.
Mechanistic framing includes diseases said to be “lysophosphatidic acid-dependent,” plus a second independent mechanism claim to “reducing signal transduction through LPAR.”

In practice, the breadth is typical of late-stage IP strategy: one or more core scaffolds are surrounded by large Markush “guardrails” to capture:

close structural variants,
alternate ring substitutions, and
different pharmaceutically acceptable salts/prodrugs.

The dependent claims then name a non-trivial subset of compounds (claim 2 and claim 21 each list many concrete examples), but those lists do not appear to limit claim 1; they narrow only in the dependent tier.

Key structural “anchors” present in the enumerated exemplars

Even with wide Markush language, the enumerated examples repeatedly use:

a carboxylic acid motif (cyclopropanecarboxylic acid or phenylacetic acid in the named set),
a substituted pyrazole core with cyano and/or fluoro/chloro substitution patterns,
an aryl/biphenyl arrangement with halogen substitutions,
a chlorophenyl ethoxycarbonylamino substituent in multiple exemplars (ethoxycarbonylamino indicates a carbamate-type protecting/connecting group in the example naming),
additional fluoro and chloro substitution patterns on the aryl rings,
some exemplars include pyridyl rings instead of phenyl.

This matters for validity and landscape because close prior art often lives in the same “anchor” region (pyrazole + carboxylic acid + halogenated biaryl motif) if the patent is from a known medicinal chemistry series.

What is the mechanism claim actually claiming?

Independent claim 20 is a functional binding/assay-style mechanism claim:

“contacting the LPAR” with a Formula I compound to reduce signal transduction.

That language can be read broadly. It does not state a specific assay endpoint, receptor subtype (LPAR1-6), binding affinity threshold, or functional readout beyond “signal transduction.”

From a freedom-to-operate and validity standpoint, that tends to raise two distinct issues:

Anticipation risk if prior art discloses the same genus compounds as LPAR antagonists/agonists in similar functional language.
Enablement/utility defenses if the patent does not provide enough data across the genus for LPAR modulation beyond a subset of exemplars.

However, the claim as written does not require a specific demonstration for each member; it relies on the genus claim being enabled and having utility at least for the claimed scope. The dependent claims strongly suggest intended utility in fibrosis/NASH/nephropathy contexts consistent with LPA biology.

Disease scope: what is “LPA-dependent disease/condition” in this patent?

Dependent claims provide explicit disease examples:

Claim 5: liver fibrosis
Claim 6: nonalcoholic steatohepatitis (NASH)
Claim 8: nephropathy
Claim 9: diabetic nephropathy
Claim 17: an expanded list including liver disease/cirrhosis/portal hypertension and a long list of conditions spanning fibrosis, inflammation, ocular disease, neuropathic pain, pruritus, AMD, diabetic retinopathy, glaucoma surgery scarring, etc.
Claim 18: narrowed to liver fibrosis, NASH, nephropathy, diabetic nephropathy

Practical scope implication

The independent claims do not limit to one organ system. Even the dependent disease list in claim 17 is broad enough that, in litigation, it could be interpreted as overreaching beyond what a given compound series was actually tested for.

In IP strategy terms, that breadth is valuable for leverage but creates attack surfaces (written description and enablement) if the disclosure is thin relative to the claimed medical uses.

Combination therapy claims: how they expand the patent’s practical moat

The dependent claims list co-therapies as “further comprising” categories.

Statins, glitazones, and RAAS blockers

Claim 7: coadminister with pioglitazone and statins (lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, nisvastatin, rosuvastatin) or chemokine receptor antagonists.
Claim 10: for diabetic nephropathy, coadminister with RAAS agents (losartan, valsartan, candesartan, irbesartan, telmisartan, olmesartan) and broad adjunct lists (mast cell stabilizers, antihistamines, ketotifen, olopatadine, rupatadine).

Large general oncology/anti-inflammatory/immune adjunct lists

Claim 15: coadminister agents across corticosteroids, immunosuppressants, analgesics, anti-cancer, anti-inflammatories, chemokine receptor antagonists, bronchodilators, leukotriene pathway drugs, PAFR antagonists, monoacylglycerol kinase inhibitors, phospholipase inhibitors, lysoPLD inhibitors, autotaxin inhibitors, and many others.
Claim 16: even larger enumeration including nearly the entire public drug universe across oncology, immunology, metabolic disease, allergy, analgesia, and more.

Claiming combinations like this

Such “laundry lists” create a patent that can be asserted against:

any protocol that includes the Formula I compound plus a listed co-therapy,
even if the co-therapy is itself standard-of-care.

But that also reduces patent defensibility if challenged under obviousness or if the combination claim is deemed not to add a novel therapeutic effect. In many jurisdictions, combination methods can survive if the patent shows a synergistic or unexpected effect tied to the claimed compound, not merely an “add another known drug” approach.

The landscape question: what matters for enforceability and design-around?

Without file history, other US family members, prosecution outcomes, and the specification text, the landscape analysis must focus on claim construction risk areas that are directly inferable from the claim text you provided.

1) Genus width invites prior art collision

Formula I’s breadth (rings, substituents, multiple variable positions) creates a high probability that at least some prior art compounds fall inside the claimed genus.

The named examples in claim 2 and 21 appear to correspond to actual medicinal chemistry structures. If those structures are disclosed in earlier publications or other patents as LPAR antagonists/modulators, US 10,570,103 is vulnerable to anticipation/obviousness attacks for members of the genus.

2) Mechanism language is not restricted by receptor subtype or functional threshold

Claim 20’s “reducing signal transduction through a lysophosphatidic acid receptor (LPAR)” does not constrain:

which LPAR subtype,
assay format,
concentration,
binding vs functional antagonism,
or degree of inhibition.

This can broaden infringement arguments but also strengthens invalidity if prior art describes LPA/LPAR modulation generally with the same compounds.

3) The disease list is extremely wide relative to the likely disclosure set

Claim 17 lists dozens of conditions spanning:

fibrosis and liver pathologies,
inflammatory disease and psoriasis,
pain and pruritus,
ocular and neuro disease,
uveitis, AMD, diabetic retinopathy,
surgical scarring,
and more.

If the specification’s experimental examples cover only a subset (for example liver fibrosis or nephropathy), claim coverage for the broader disease list becomes a written description/enablement flashpoint.

4) Dependent co-therapy lists are broad enough to be attacked as obvious

Claim 15 and 16’s co-therapy lists span widely known drugs with many established indications. In obviousness analysis, the patentee would need to show the combination with Formula I is not merely the predictable addition of a known therapy.

If the patent does not tie LPAR modulation to a specific combination effect for each enumerated group, a challenger can argue these are routine modifications.

Where this patent likely sits in the LPA therapeutic IP ecosystem

US 10,570,103 is positioned as:

an LPAR-targeting small-molecule series (not biologics),
with claimed utility across fibrosis and metabolic-inflammatory disease (NASH) and nephropathy,
using a broad genus and extensive substituent freedom.

In a typical LPA landscape, prior art often clusters around:

small molecules that bind LPARs (or modulate LPA signaling),
inhibitors of upstream LPA generation (e.g., autotaxin/lysoPLD inhibitors),
and combination strategies using standard-of-care drugs in fibrosis/metabolic disease.

This patent appears to focus on the receptor-facing small-molecule genus while also attempting to capture combination therapy value broadly (including lysoPLD/autotaxin inhibitor co-therapy in claim 15).

Critical take: which claim features are strongest vs weakest?

Stronger claim elements (more likely to preserve coverage)

Structural core: Claim 1 and 11 lock onto Formula I’s scaffold with extensive but bounded chemistry. If that scaffold is not disclosed in prior art, novelty and nonobviousness improve.
Specific exemplar compounds: Claim 3 and 4 identify particular compounds. If those specific structures are truly novel and not published earlier, those dependents are defensible even if the broader genus is attacked.
Treatment framing tied to LPA dependence: this is coherent with known LPA biology and fibrosis/nephropathy therapeutic hypotheses.

Weaker claim elements (highest attack surface)

Genus breadth: large Markush ranges increase prior art collision probability.
Mechanism breadth: lack of receptor subtype or functional threshold.
Overbroad disease list: claim 17’s breadth is large relative to typical single-series in vivo testing scope.
Combination therapy laundry lists: huge enumerations of common drugs can be attacked as obvious or not supported by specific unexpected results.

What would matter most in a validity and infringement assessment (claim-by-claim)?

For infringement

Determine whether a competitor compound falls within Formula I as construed:
- Does it match the anchor motif (carboxylic acid/carboxylic acid isostere), pyrazole scaffold, biaryl/heteroaryl ring attachments, and the allowed heterocycle/ring constraints?
For method claims, confirm whether the competitor labels or uses the compound for an LPA-dependent disease/condition covered by dependent claims or the broad independent claim.
For claim 20, confirm whether competitor’s use includes “contacting the LPAR” in a meaningful sense (in vivo administration usually satisfies “contacting” arguments) and whether it reduces LPAR signal transduction.

For validity

Map each named exemplar (claim 2/21 list) to:
- earlier patents/publications,
- chemical databases and compound synthesis references,
- and any LPAR functional assay disclosures.
Challenge the genus:
- anticipation for specific members,
- obviousness for structural variants,
- and genus enablement/written description for the full range, using the sheer breadth of substituent definitions as the attack anchor.
Attack overbreadth of disease list:
- if only fibrosis/NASH/nephropathy were tested, other indications in claim 17 create written description/enablement risk.

Key Takeaways

US 10,570,103 is a broad LPAR-directed small-molecule patent built around a Formula I Markush genus with extensive substituent coverage and parallel treatment and mechanism claims.
The claim strength is tied to whether the specific scaffold exemplars and key anchor motifs are novel versus prior disclosures of LPAR modulators.
The main vulnerability is the breadth: the Markush structure and oversized disease and combination therapy lists expand claim scope while increasing prior art and disclosure-support attack surfaces.
Dependent claims provide useful narrower targets (specific exemplars; liver fibrosis/NASH/nephropathy/diabetic nephropathy), but they do not fully immunize the broad independent genus claims.

FAQs

1) Does US 10,570,103 claim only one compound?
No. Claim 1 (and 11) claims a genus defined by Formula I with extensive Markush variable definitions. Dependent claims then list specific exemplar compounds.

2) What does claim 20 add beyond claim 1?
Claim 20 adds a mechanism-style method: contacting LPAR with a Formula I compound to reduce “signal transduction,” without restricting receptor subtype or assay threshold.

3) Are liver fibrosis and NASH explicitly covered?
Yes. Claim 5 covers liver fibrosis and claim 6 covers nonalcoholic steatohepatitis (NASH).

4) What is the biggest reason the patent may face validity pressure?
The combination of a very broad Markush genus and a very broad set of therapeutic indications and co-therapies increases prior art collision and written description/enablement and obviousness attack surfaces.

5) Do the co-therapy lists strengthen enforceability or weaken it?
They can strengthen enforceability by expanding the ways a method could be argued to infringe, but the breadth (especially in claim 16) increases obviousness and lack-of-supported-unexpected-effect risk in validity challenges.

References (APA)

[1] United States Patent No. 10,570,103 (claims text provided in prompt).

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	January 10, 1978	⤷ Start Trial	2038-06-05
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132	June 04, 1986	⤷ Start Trial	2038-06-05
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132		⤷ Start Trial	2038-06-05
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	Injection	103132		⤷ Start Trial	2038-06-05
Hoffmann-la Roche Inc.	ROFERON-A	interferon alfa-2a	For Injection	103145	June 04, 1986	⤷ Start Trial	2038-06-05
Aim Immunotech Inc.	ALFERON N INJECTION	interferon alfa-n3 (human leukocyte derived)	Injection	103158	October 10, 1989	⤷ Start Trial	2038-06-05
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,570,103

Summary for Patent: 10,570,103